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X Dhruva D. Dhavale, Christina Tsai, Devika P. Bagchi, Laura A. Engel, Jonathan Sarezky, and Paul T. Kotzbauer1
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Edited by Paul E. Fraser

Parkinson’s disease (PD)2 is a debilitating, progressive neurodegenerative disorder characterized by impaired movement
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and additional non-motor symptoms. Accumulation of misfolded ␣-synuclein (␣-syn) in cytoplasmic and neuritic inclusions known as Lewy bodies and Lewy neurites is the defining
pathologic feature of idiopathic PD (1–3). ␣-Syn is a 140-amino
acid protein that is highly soluble and normally localized to
neuronal presynaptic terminals (4, 5). In PD, it aggregates to
form insoluble fibrils, the primary component of Lewy bodies
and Lewy neurites (6, 7). Pathologic ␣-syn accumulation occurs
in multiple brain regions, including the substantia nigra pars
compacta, locus coeruleus, raphe nuclei, substantia innominata, olfactory bulbs, amygdaloid nuclei, and cerebral cortex (8,
9). Disease progression, specifically the development of dementia in PD, correlates with more widespread ␣-syn deposition
(10 –12).
A pathogenic role for ␣-syn is supported by the identification
of dominantly inherited ␣-syn (SNCA) gene mutations in rare
familial forms of PD, including missense mutations (A30P,
E46K, A53T, H50Q, and G51D) as well as duplication and triplication of the SNCA locus. These hereditary disorders are
also characterized by pathologic ␣-syn accumulation (13–20).
Understanding the mechanisms by which ␣-syn mutations
cause fibril accumulation could provide further insight into
pathogenic processes and therapeutic targets for both sporadic
and familial PD.
The spontaneous conversion of monomeric protein to fibrils
depends on an initial nucleation event, in which two or more
monomers associate to form seeds, followed by fibril growth, in
which monomeric protein sequentially associates with existing
seeds (2, 21, 23, 24). The formation of ␣-syn fibrils during incubation of purified monomeric protein can be detected by amyloid binding dyes, such as thioflavin T (ThioT), or by detection
of sedimented fibrils. Soluble oligomeric species, distinguishable from fibrils based on sedimentation properties, can be separated from monomeric protein by size-exclusion chromatography (SEC) before immunodetection (25).
Previous studies of spontaneous ␣-syn aggregation have
shown that the A53T and H50Q mutations increase the rate at
which monomeric protein is converted to fibrils (21, 26 –28). In
contrast, the A30P and G51D mutations have been shown to
decrease the rate of fibril formation but may increase the rate of
soluble oligomer formation compared with WT ␣-syn (29, 30).
In the case of the E46K mutation, most studies have reported
AFM, atomic force microscopy; WB, Western blot; DLS, dynamic light scattering; FlAsH-EDT2, 4,5-bis(1,3,2-dithiarsolan2-yl)fluorescein; afu, arbitrary
fluorescence units.
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The accumulation of ␣-synuclein (␣-syn) fibrils in neuronal
inclusions is the defining pathological process in Parkinson’s
disease (PD). A pathogenic role for ␣-syn fibril accumulation is
supported by the identification of dominantly inherited ␣-syn
(SNCA) gene mutations in rare cases of familial PD. Fibril formation involves a spontaneous nucleation event in which soluble ␣-syn monomers associate to form seeds, followed by fibril
growth during which monomeric ␣-syn molecules sequentially
associate with existing seeds. To better investigate this process,
we developed sensitive assays that use the fluorescein arsenical
dye FlAsH (fluorescein arsenical hairpin binder) to detect soluble oligomers and mature fibrils formed from recombinant
␣-syn protein containing an N-terminal bicysteine tag (C2-␣syn). Using seed growth by monomer association (SeGMA)
assays to measure fibril growth over 3 h in the presence of C2␣-syn monomer, we observed that some familial PD-associated
␣-syn mutations (i.e. H50Q and A53T) greatly increased growth
rates, whereas others (E46K, A30P, and G51D) decreased
growth rates. Experiments with wild-type seeds extended by
mutant monomer and vice versa revealed that single-amino acid
differences between seed and monomer proteins consistently
decreased growth rates. These results demonstrate that ␣-syn
monomer association during fibril growth is a highly ordered
process that can be disrupted by misalignment of individual
amino acids and that only a subset of familial-PD mutations
causes fibril accumulation through increased fibril growth rates.
The SeGMA assays reported herein can be utilized to further elucidate structural requirements of ␣-syn fibril growth and to identify growth inhibitors as a potential therapeutic approach in PD.

Structural determinants of ␣-synuclein fibril growth

faster aggregation than WT ␣-syn, whereas one study reported
a longer lag time relative to WT (31–34). Several studies have
investigated interactions between mutant and WT ␣-syn proteins during fibril formation, with mixed results as to how they
influence ␣-syn fibril accumulation in individuals with dominantly inherited PD (21, 34 –36).
To further characterize structural determinants and mechanisms underlying fibril formation, we developed assays that use
the biarsenical dye fluorescein arsenical hairpin binder (FlAsH)
to detect the association of two or more ␣-syn monomers containing bicysteine tags. FlAsH is a profluorescent biarsenical
dye that binds to short peptides containing four cysteine
residues (37, 38). The intermolecular association of two peptides can also be monitored by biarsenical dyes when each of
the two peptides contains a peptide tag with two cysteine
residues (39 – 42). In this bipartite tetracysteine approach,
close association (⬃10 Å) of the bicysteine tags in assembled
complexes is required to bind FlAsH and induce fluorescence (40).
We found that FlAsH has high sensitivity and specificity for
the detection of both soluble oligomeric species and fibrils
formed by bicysteine-tagged ␣-syn (C2-␣-syn). Additionally,
the high sensitivity of FlAsH for oligomeric and fibrillar ␣-syn
can be utilized to establish novel seed growth by monomer
association (SeGMA) assays, which measure the rate at which
monomer is consecutively added to preformed seeds consisting
of either soluble oligomers or fibrils. We examined the effects
of ␣-syn mutations on seed growth rates and found that some
PD-associated mutations significantly increase the rate,
whereas others significantly decrease the rate. Furthermore, in
SeGMA assays in which the sequence of monomer protein
differs from the sequence of seeds, we observed that singleamino acid mismatches between seeds and monomer frequently decrease the rate of fibril growth.

Results
Bipartite tetracysteine tags enable detection of ␣-syn fibril
formation
To determine whether the formation of ␣-syn fibrils can be
detected with a bipartite tetracysteine reporter, we produced
recombinant human C2-␣-syn protein.
We incubated native ␣-syn and C2-␣-syn protein at 37 °C
with shaking to form fibrils. The temporal profiles of fibril formation using native ␣-syn versus C2-␣-syn, measured by ThioT
fluorescence, were very similar (Fig. 1A), indicating that the
bicysteine tag does not alter the rate of fibril formation. We next
examined the ability of the FlAsH dye to detect fibril formation
and observed a robust increase in fluorescence upon formation
of C2-␣-syn amyloid fibrils, which paralleled the increase in
ThioT fluorescence (Fig. 1B). In contrast, FlAsH fluorescence
did not increase in the presence of native WT ␣-syn fibrils. We
further characterized FlAsH detection of C2-␣-syn fibrils by
combining 25 nM FlAsH with increasing concentrations of
C2-␣-syn fibrils and measuring fluorescence. Analysis of the
data with a saturation binding model indicated that the average
apparent affinity constant (Kapp) for association of FlAsH with
C2-␣-syn fibrils is 27 g/ml (Fig. 1C). Atomic force microscopy
(AFM) verified that native ␣-syn and C2-␣-syn fibrils have similar morphology (Fig. 1, D–G), providing further evidence that
the C2 tag does not significantly alter the ␣-syn fibril formation
process. Fibril formation reactions contained freshly added
dithiothreitol (DTT) to reduce disulfides formed by cysteine
residues. In our early fibril formation experiments performed in
the absence of DTT, C2-␣-syn formed fibrils at a slightly faster
rate compared with native ␣-syn (data not shown). When DTT
was added in subsequent experiments, rates were more similar,
as shown in Fig. 1A.
J. Biol. Chem. (2017) 292(22) 9034 –9050
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Figure 1. Bipartite tetracysteine detection of C2-␣-syn fibril formation using FlAsH dye. A, similar kinetic profiles are observed when ThioT is used
to monitor fibril formation by WT ␣-syn and WT C2-␣-syn. B, formation of fibrils by WT C2-␣-syn can be measured by FlAsH fluorescence and displays a
profile similar to that observed with ThioT. C, a saturation binding assay using increasing concentrations of C2-␣-syn fibrils incubated with 25 nM FlAsH
indicates a Kapp of 23 g/ml of FlAsH to C2-␣-syn fibrils. D–G, AFM analysis shows similar morphology of WT ␣-syn fibrils (D and E) and WT C2-␣-syn fibrils
(F and G) formed following incubation for 72 h. Similar results were observed in three independent experiments (mean ⫾ S.E. (error bars), n ⫽ 3).
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Figure 2. FlAsH detects soluble ␣-syn oligomers. Samples of WT ␣-syn and WT C2-␣-syn monomer incubated for 32 h were centrifuged at 100,000 ⫻ g, and
supernatants were fractionated by SEC. A and B, Western blot analysis for ␣-syn in SEC fractions reveals ␣-syn oligomers in early, high-Mr fractions, in addition
to ␣-syn monomer in late, low-Mr fractions (not shown). Similar amounts of oligomeric ␣-syn are present in high-Mr fractions from WT ␣-syn (A) and WT
C2-␣-syn (B) reactions. C, oligomeric ␣-syn species are detected by FlAsH fluorescence in high-Mr fractions. The specificity of FlAsH for oligomeric species is
demonstrated by the absence of FlAsH fluorescence in low-Mr fractions containing high levels of ␣-syn monomer detected by WB. D, FlAsH detects oligomeric
species only after incubation of purified ␣-syn monomer, and ThioT has poor sensitivity for detecting soluble oligomers present in SEC fractions. E, FlAsH
analysis of SEC fractions demonstrates progressive accumulation of ␣-syn oligomers with increasing incubation time. F, calibration curve obtained by fractionating Mr standards on the SEC column. G–J, AFM analysis of WT ␣-syn (G and H) and WT C2-␣-syn (I and J) oligomers show similar morphology. Similar results
were observed in two independent experiments.

FlAsH detects soluble ␣-syn oligomers
To characterize soluble oligomeric ␣-syn species, we incubated native ␣-syn and C2-␣-syn monomer at 37 °C for 32 h,
centrifuged the samples at 100,000 ⫻ g, and then fractionated
the supernatants using SEC. Western blot (WB) analysis demonstrated that ␣-syn elutes from the column in two distinct
peaks: a high-Mr oligomer peak eluting near the void volume
(relative Mr ⫽ 1,100,000) and a lower-Mr peak eluting at a relative Mr of 59,000 (Fig. 2, A–C). SEC analysis of recombinant
␣-syn that was not previously incubated at 37 °C demonstrated

9036 J. Biol. Chem. (2017) 292(22) 9034 –9050

only the low-Mr peak. WB analysis indicated that native ␣-syn
and C2-␣-syn produced similar levels of high-Mr oligomer species when incubated at 37 °C for 32 h.
We analyzed the C2-␣-syn SEC fractions in the FlAsH fluorescence assay. We observed increased fluorescence exclusively
in high-Mr fractions, corresponding to the ␣-syn identified by
WB in these fractions. Despite the presence of substantially
higher levels of ␣-syn in WB analysis of the low-Mr fractions,
there was no increase in FlAsH fluorescence above baseline,
confirming both the specificity of the FlAsH assay for high-Mr

Structural determinants of ␣-synuclein fibril growth

oligomer species and the absence of oligomeric species in the
lower-Mr peak (Fig. 2C).
In a separate experiment, we compared the abilities of ThioT
and FlAsH to detect soluble oligomers present in SEC fractions
from C2-␣-syn incubated for 32 h. FlAsH produced a robust
increase in fluorescence for high-Mr SEC fractions of incubated
C2-␣-syn, compared with non-incubated C2-␣-syn. In contrast, we did not detect a change in ThioT fluorescence for
high-Mr SEC fractions (Fig. 2D) regardless of incubation time.
These results demonstrate that FlAsH detects soluble high Mr
oligomers that do not bind ThioT.
To examine the temporal evolution of oligomeric species, we
used FlAsH to analyze SEC fractions obtained after C2-␣-syn
was incubated for varying lengths of time. Oligomer levels progressively increased with longer incubation times (Fig. 2E). The
distribution of FlAsH-positive oligomers was similar among
several time points, with significant FlAsH fluorescence present
in fractions corresponding to relative Mr values of 440,000 and
higher, based on comparison with a Mr standard calibration
curve (Fig. 2F).
AFM characterization of ␣-syn oligomers
We used AFM to further characterize ␣-syn oligomers detected
by FlAsH. AFM images revealed a combination of spherical and
ellipsoid species. Native ␣-syn (Fig. 2, G and H) and C2-␣-syn (Fig.
2, I and J) oligomers displayed similar morphologies.
SeGMA assay with soluble oligomers
The ability of FlAsH to detect both soluble oligomers and
fibrils suggested that it could also quantitatively detect the
sequential addition of monomer involved in the conversion of
oligomers to mature fibrils. To determine whether SEC-purified oligomers function as seeds that can grow in the presence
of monomer, we developed a SeGMA assay (Fig. 3A) in which
SEC-purified soluble oligomers were incubated with purified
C2-␣-syn monomer, and the association of monomer with

seeds was detected by FlAsH. As a control, we incubated purified C2-␣-syn monomer with SEC fractions that were derived
from C2-␣-syn monomer incubated for 0 h. We observed a
time-dependent increase in FlAsH fluorescence for reactions
containing C2-␣-syn oligomers plus C2-␣-syn monomer (Fig. 3B).
In control reactions containing C2-␣-syn monomer and control
SEC fractions, FlAsH signal did not change significantly over the
3-h incubation period, reflecting the low nucleation rate of purified monomer at the concentrations used in the assay.
SeGMA assay with sonicated fibrils
In the fibril formation experiments, we estimated an oligomer/fibril ratio of ⬍ 1% after incubation of purified C2-␣-syn
monomer for 72 h, indicating that kinetics favor conversion to
fibrils. To further characterize seed extension by sequential
association of monomer using fibrils as seeds, we used a water
bath sonicator to fragment and disperse fibrils obtained after a
72-h incubation of C2-␣-syn. Characterization of these seeds by
dynamic light scattering (DLS) indicated consistent size distribution and concentration across independently generated
batches (Table 1). Incubation of 30 g/ml sonicated fibrils with
500 g/ml C2-␣-syn monomer in SeGMA assays produced a
linear increase in FlAsH signal over 4.5 h. In control reactions
with no added fibril seeds, FlAsH signal did not increase,
reflecting the absence of spontaneous nucleation over the 4.5-h
incubation period (Fig. 3C).
FlAsH is more sensitive than ThioT for measuring fibril growth
rates
To compare the sensitivity of FlAsH and ThioT in SeGMA
assays, we incubated different amounts of sonicated C2-␣-syn
fibril seeds with 500 g/ml C2-␣-syn monomer for 3 h and
quantified seed extension with either FlAsH (Fig. 4A) or ThioT
(Fig. 4B). We observed a linear increase for both FlAsH and
ThioT fluorescence with respect to seed concentration. However, the signal/background ratio was substantially higher for
J. Biol. Chem. (2017) 292(22) 9034 –9050
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Figure 3. FlAsH detects extension of oligomer and fibril seeds by association of WT C2-␣-syn monomer. A, diagram of the conceptual basis for the SeGMA assay.
When SEC-isolated oligomers or sonicated fibril seeds are incubated with C2-␣-syn monomer at 37 °C, C2-␣-syn monomer sequentially associates with seeds, which
can then be detected by binding of FlAsH dye to closely associated C2-␣-syn monomers. B and C, results of SeGMA assays in which SEC-isolated oligomers (B) or
sonicated fibril seeds (30 g/ml) (C) were incubated with WT C2-␣-syn monomer (500 g/ml) for different lengths of time. A linear increase in FlAsH fluorescence
indicates that FlAsH detects sequential association of monomer with seeds. No change in FlAsH fluorescence is detected when WT C2-␣-syn is incubated
with control SEC fractions or fibril buffer (“no seeds”). Similar results were observed in three independent experiments (mean ⫾ S.D. (error bars), n⫽3).

Structural determinants of ␣-synuclein fibril growth
Table 1
Estimation of WT and mutant fibril seed size
DLS was used to determine the intensity-weighted hydrodynamic diameter of the sonicated seeds (z-average) (diameter in nm ⫾ S.D.) and the average polydispersity
intensity ⫾ S.D. for each of the WT and mutant fibrils used in the seed extension experiments. The results show similar sizes of WT and mutant fibril species. All
polydispersity intensity values were ⬍ 0.7, indicating that the samples are sufficiently monodispersed to yield reliable z-average measurements.
C2-␣-syn fibril seeds

Z-average (diameter ⴞ S.D.)

PDI (average ⴞ S.D.)

Independent measurements (n)

0.245 ⫾ 0.02
0.263
0.276
0.187 ⫾ 0.16
0.244 ⫾ 0.04
0.306 ⫾ 0.04
0.260 ⫾ 0.02

10
2
2
6
6
6
10

nm

WT
A30P
A53T
E46K
G51D
H50Q
Fibril buffer

57.0 ⫾ 2.9
57.0
72.2
80.8 ⫾ 7.0
67.9 ⫾ 6.0
53.5 ⫾ 3.8
8.9 ⫾ 0.2

FlAsH fluorescence compared with ThioT fluorescence for the
lower levels of fibril formation in SeGMA assays. We calculated
the Z⬘-factor as an estimate of the dynamic range and separation band for assays measuring seed extension by FlAsH and
ThioT (Table 2). Assays with FlAsH produced a Z⬘-factor
between 0.62 and 0.96 for all fibril seed concentrations tested in
the SeGMA assay, indicating robust assay performance and
suitability as a screening assay. Z⬘-Factors for ThioT assays
were in the range of 0.00 – 0.26, indicating smaller separation
bands and marginal assay performance. We used the same conditions, 11.5 g/ml C2-␣-syn fibril seeds, and 500 g/ml C2-␣syn monomer to compare the signal/background ratio for
FlAsH (Fig. 4C) and ThioT (Fig. 4D) over 96 h of fibril growth
and also saw a higher signal/background ratio for FlAsH compared with ThioT during the longer incubation time. At 96 h,
the signal/background ratio was 26.2 for FlAsH and 2.1 for
ThioT. The advantage of FlAsH over ThioT was less pro-
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nounced for the measurement of fibril formation when ␣-syn
monomer was incubated at higher concentrations with shaking
(Fig. 1), where the amount of fibril formation was ⬃20-fold
higher, based on measurement of fibril concentration by a BCA
sedimentation assay.
Familial-PD mutations alter fibril growth rates
To determine the effects of familial PD-associated ␣-syn
mutations on the kinetics of fibril formation, we measured seed
growth rates for C2-WT and mutant C2-␣-syn seeds combined
with corresponding C2-WT and mutant C2-␣-syn monomer
proteins (homologous SeGMA assay). We incubated 11.5
g/ml seeds with 500 g/ml C2-␣-syn monomer for various
lengths of time (0 –5 h) and measured growth rates in the FlAsH
assay (Fig. 5, A and B). All five missense amino acid mutations
altered the rate of seed extension relative to WT. The A53T and
H50Q mutations increased the rate of seed extension to 460

Downloaded from http://www.jbc.org/ at Washington University on July 29, 2017

Figure 4. FlAsH has greater sensitivity compared with ThioT for detection of fibril growth. Increasing concentrations of sonicated fibril seeds (0 –14.5
g/ml) were incubated with C2-␣-syn monomer (500 g/ml) for 3 h, and the reactions were analyzed with either FlAsH (A) or ThioT (B) fluorescence assays
(mean ⫾ S.D. (error bars), n ⫽ 3, independent experiments ⫽ 2). The signal/background (3 h/0 h) ratio for FlAsH fluorescence is significantly greater than ThioT
fluorescence at all concentrations of seeds in the SeGMA assay. Comparison of Z⬘-factors for each measurement demonstrates more robust assay performance
for FlAsH (shown in Table 2). To compare signal/background ratios over longer time periods, 11.5 g/ml C2-␣-syn seeds and 500 g/ml C2-␣-syn monomer
were incubated at 37 °C without agitation for varying lengths of time up to 96 h. Fibril growth at each time point was determined by FlAsH (C) or ThioT (D)
fluorescence. Although signal/background ratios for ThioT improved with increasing incubation time, they were significantly lower compared with FlAsH.

Structural determinants of ␣-synuclein fibril growth
Table 2
Zⴕ-factor analysis of FlAsH and ThioT performance in SeGMA assays
WT C2-␣-syn seeds at concentrations ranging from 3.6 to 14.5 g/ml were incubated with 500 g/ml C2-␣-syn monomer for 3 h and fluorescence-quantified by FlAsH and
ThioT (mean ⫾ S.D., n ⫽ 3, independent experiments ⫽ 2). The Z⬘-factor was calculated for fluorescence measured at 3 h for each seed concentration and the
corresponding control at 0 h.
FlAsH fluorescence
Seed concentration

3h

0h

g/ml

afu ⫾ S.D.

afu ⫾ S.D.

3315 ⫾ 59
12,815 ⫾ 401
24,278 ⫾ 88.5
48,310 ⫾ 774.5

3047.6 ⫾ 12.2
6742 ⫾ 373.9
10,584 ⫾ 113
19,179.3 ⫾ 870

0.00
3.6
7.2
14.5

ThioT fluorescence
Zⴕ-Factor

0.62
0.96
0.83

3h

0h

afu ⫾ S.D.

afu ⫾ S.D.

8807 ⫾ 670
9933.3 ⫾ 131
11,147.6 ⫾ 87
13,807 ⫾ 309

8362.5 ⫾ 199.5
9238.5 ⫾ 76.5
9660.5 ⫾ 277.5
10,607 ⫾ 755

Zⴕ-Factor

0.10
0.26
0.00

Table 3
De novo fibril formation at 72 h assessed by BCA assay
Shown are the fibril concentrations (g/ml) obtained when 2000 g/ml WT and mutant C2-␣-syn monomer preparations were incubated at 37 °C with shaking for 72 h,
which produces fibril formation by spontaneous nucleation (mean ⫾ S.D.). Differences in the amount of fibrils accumulating in the de novo fibril formation system are
similar to the differences observed for WT and mutant fibril accumulation in the homologous SeGMA assays.
WT

A30P

A53T

E46K

G51D

H50Q

912 ⫾ 93 (n ⫽ 9)

543 ⫾ 171 (n ⫽ 4)

1304 ⫾ 224 (n ⫽ 5)

604 ⫾ 286 (n ⫽ 9)

423 ⫾ 159 (n ⫽ 5)

1320 ⫾ 76 (n ⫽ 8)

and 283% of the rate of WT, respectively. In contrast, the E46K,
G51D and A30P mutations decreased the seed extension rate to
60, 42, and 30% of WT, respectively (Fig. 5C). Similar results
were observed in multiple independent experiments.
Fibrils used in SeGMA assays were produced by incubating
2000 g/ml C2-␣-syn monomer at 37 °C with shaking for 72 h.
We used a BCA assay to measure the amount of fibrils produced by WT and mutant C2-␣-syn under these conditions, in
which higher monomer concentrations and shaking are used to
promote nucleation and fibril growth (Table 3). Comparison of
fibril production rates for WT and mutant C2-␣-syn revealed
differences that were similar to those observed for WT and
mutant C2-␣-syn in SeGMA assays. A53T and H50Q produced
higher levels of fibrils at 72 h, whereas A30P, E46K, and G51D
produced lower levels of fibrils.
To evaluate whether the sensitivity of FlAsH for measuring
fibrils varies among different fibril species, we measured FlAsH
fluorescence for equal concentrations of WT and mutant C2-␣syn fibrils (Table 4). Most mutant fibril species produced FlAsH
fluorescence values that were similar to WT. FlAsH sensitivity
was modestly lower for G51D fibrils, suggesting that the results
in Fig. 5C may overestimate the degree to which G51D seed

extension is slower than WT. We used DLS to measure the
average size of WT and mutant C2-␣-syn fibril seeds produced
by sonication. The hydrodynamic radius (z-average) measurements indicated consistent sizes across multiple independent
seed preparations. Differences in the size of WT and mutant
seeds were modest and did not account for the observed differences in seed extension rates (Table 1).
Single-amino acid mismatches decrease heterologous fibril
growth rates
In individuals with dominantly inherited PD who have one
mutant SNCA allele and one WT SNCA allele, ␣-syn fibril
accumulation can also be influenced by interactions between
mutant and WT ␣-syn protein. We determined the effects of
␣-syn mutations in heterologous SeGMA assays, in which
either C2-␣-syn WT seeds were extended by association of
mutant C2-␣-syn monomer or C2-␣-syn mutant seeds were
extended by association of WT monomer. We measured fibril
growth rates for each combination of seed and monomer and
then determined average rates based on measurements at multiple seed concentrations (Fig. 6). We then compared rates of
heterologous seed extension (Fig. 7, B and C) with that of hoJ. Biol. Chem. (2017) 292(22) 9034 –9050
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Figure 5. Comparison of homologous fibril growth rates for WT and mutant C2-␣-syn. The rate of fibril growth was measured by FlAsH fluorescence after
incubating homologous combinations of 500 g/ml C2-␣-syn monomer with 11.5 g/ml matched preformed fibril seeds for different lengths of time. A,
comparison of WT, A30P, and A53T C2-␣-syn; B, comparison of WT, E46K, G51D, and H50Q C2-␣-syn; C, bar graph shows the average rates of mutant ␣-syn fibril
growth (A30P, A53T, E46K, G51D, and H50Q) as a percentage of the rate of WT ␣-syn (mean ⫾ 95% confidence interval (error bars), n ⫽ 3, independent
experiments ⫽ 2).

Structural determinants of ␣-synuclein fibril growth
mologous seed extension (Fig. 7A), in which seeds and monomer were matched. Relative rates of homologous seed extension in this paradigm were similar to those observed in the
homologous SeGMA time course experiments (Fig. 5). Mismatches between seeds and monomer sequences significantly
decreased rates of fibril growth. When WT seeds were incubated with mutant monomers, we observed very low fibril
growth rates, with the exception of WT seeds extended by
H50Q monomer (Fig. 7B). In the case of H50Q monomer association with WT seeds, the rate was similar to the rate of WT
monomer association with WT seeds, but this rate was only
33% of the rate of H50Q monomer association with H50Q
seeds. Furthermore, when mutant seeds were incubated with
WT monomer (Fig. 7C), we observed consistently low rates
ranging from 7.6 to 30% of the rate of extension of WT seeds.
The homologous and heterologous fibril growth rates are sum-

To examine whether differences in FlAsH sensitivity for WT and mutant fibril
species contribute to differences in measured rates of fibril growth, fluorescence was
measured when equal concentrations of WT and mutant fibrils (14.5 g/ml) were
incubated with FlAsH dye. Data were normalized to fluorescence obtained from
WT C2-␣-syn fibrils. Similarities in fluorescence signal between WT and mutant
fibril species support the use of FlAsH for reliable comparisons of WT and mutant
fibril growth rates (mean ⫾ S.D., n ⫽ 6, independent experiments ⫽ 2).
WT

A30P

A53T

E46K

G51D

H50Q

%

%

%

%

%

%

100 ⫾ 15

85.2 ⫾ 16

82.7 ⫾ 29

107.6 ⫾ 6.9

72 ⫾ 5.6

106.9 ⫾ 15.4

Figure 6. Reduced rates of heterologous fibril growth. Reduced rates of heterologous fibril growth for both WT seeds extended by mutant monomer and
mutant seeds extended by WT monomer for 3 h. A–E, homologous fibril growth experiments in which the seeds and monomeric ␣-syn protein species were
matched. Graphs show comparison of rates for WT seeds extended by WT monomer with the rates for each of the individual mutant seeds extended by the
same mutant monomer, at seed concentrations ranging from 2.9 to 11.5 g/ml. F–J, heterologous fibril growth experiments in which WT seeds were extended
by mutant monomeric C2-␣-syn proteins. Each graph shows a comparison of the rates for WT seeds extended by WT monomer with the rates for WT seeds
extended by each individual mutant monomer. K–O, heterologous fibril growth experiments in which each of the mutant seeds was extended with WT
C2-␣-syn monomer. Each graph shows a comparison of the rates for WT seeds extended by WT monomer with the rates for each individual mutant seed
extended by WT monomer (mean ⫾ S.D. (error bars), n ⫽ 3, independent experiments ⫽ 2).
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Table 4
FlAsH fluorescence intensity in the presence of equal concentrations
of WT and mutant C2-␣-syn fibrils as a percentage of WT value

marized in Table 5. These results demonstrate that singleamino acid mismatches in the N-terminal region of ␣-syn significantly alter the rate of fibril growth.
Because individuals with dominantly inherited ␣-syn gene
mutations have a combination of WT and mutant ␣-syn protein production, we measured fibril growth rates for each
seed species in the presence of 50% WT and 50% mutant
␣-syn monomer (Fig. 8). Overall, the rates produced by WT
and mutant mixtures were very close to the average of the
individual rates for WT and each mutant monomer (Fig. 6),
indicating that rates produced by monomer mixtures are
equal to the sum of the individual monomer rates, with no
evidence of synergistic interactions between WT and mutant
proteins.
We also examined homologous and heterologous seeded
fibril growth over 96 h using the same concentrations of seeds
(11.5 g/ml) and monomer (500 g/ml) used for 3-h rate measurements (Fig. 9 and Table 6). The relative rates measured over
longer time periods were consistent with 3-h rate measurements for homologous seed-monomer combinations. Most
seed-monomer combinations eventually reached equilibrium
states, in which the amount of fibrils measured by FlAsH
remained constant. The faster rates of A53T and H50Q translated into higher levels of fibrils at equilibrium relative to WT,
whereas the slower rates of A30P, E46K, and G51D translated
to lower levels of fibrils at 96 h.
The rates of heterologous seeded fibril growth were also consistent between 3- and 96-h experiments. For example, the slow
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Figure 7. Reduced rates of heterologous fibril growth for both WT seeds
extended by mutant monomer and mutant seeds extended by WT monomer. Rates of homologous and heterologous fibril growth were compared for
different concentrations of seeds incubated with a fixed concentration of
monomer for 3 h. All data were normalized to the rate of WT seeds extended
by WT monomer. A, normalized data show the rate of fibril growth when the
same species of preformed fibril seeds and C2-␣-syn monomer protein were
used in each reaction. B, normalized data show the rate at which WT C2-␣-syn
seeds were extended by either WT or mutant (A30P, A53T, E46K, G51D, and
H50Q) C2-␣-syn monomer. C, normalized data show the rate of extension of
WT or mutant (A30P, A53T, E46K, G51D, and H50Q) C2-␣-syn seeds with WT
monomer (mean ⫾ 95% confidence interval (error bars), n ⫽ 3, independent
experiments ⫽ 2). The average rate of fibril growth was determined using
four different concentrations of seeds during a 3-h incubation period (shown
in Fig. 6) and is expressed as a percentage of the rate for WT seeds extended
by WT monomer. Because all rates were normalized to the rate of WT seeds
extended by WT monomer, rates of homologous and heterologous fibril
growth can be compared across the three graphs.

growth of WT seeds in the presence of A53T monomer was
maintained over 96 h, which indicates that the structural feature of WT fibrils dictating slow A53T monomer association

Discussion
In this study, we developed a novel assay that utilizes bipartite tetracysteine detection to analyze the effects of single-amino acid sequence changes on fibril growth, a critical step in
␣-syn fibril accumulation. To that effect, we produced recombinant ␣-syn protein containing a bicysteine tag. We demonstrated that FlAsH is capable of detecting a wide range of soluble oligomeric and fibrillar species produced by incubation of
the monomeric C2-␣-syn protein. This property enabled the
development of a highly sensitive in vitro SeGMA assay that
measures the rate of monomeric ␣-syn association with either
preformed oligomer or fibril seeds. We observed that two
mutations associated with familial PD (H50Q and A53T) dramatically increase the rate of seed extension, whereas three
mutations (A30P, E46K, and G51D) significantly decrease the
rate of seed extension. Our heterologous seed extension experiments demonstrated that WT seeds are extended inefficiently
J. Biol. Chem. (2017) 292(22) 9034 –9050
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remains stable despite the sequential addition of A53T monomer. Stable maintenance of fibril structure, as reflected by
monomer association rates, was observed for all of the heterologous seed-monomer combinations.
We compared FlAsH measurements with two other measurements of fibril formation after 96 h of seeded fibril growth (Fig.
10). In addition to ThioT measurements, we used a BCA sedimentation assay, which measures the concentration of fibrils by
determining the change in monomer concentration in the
supernatant between 0 and 96 h following centrifugation at
100,000 ⫻ g for 20 min. We focused on measuring fibril formation after 96 h of seeded fibril growth, because the sensitivities
of ThioT and BCA assays were not optimal for quantifying fibril
growth during shorter time periods. The amount of fibril formation determined by BCA sedimentation assays strongly correlated with the amount of fibril formation determined by
FlAsH for the same reactions. Relative rates of fibril formation
determined by ThioT measurements also generally agreed with
FlAsH measurements, although ThioT generally showed that
heterologous growth rates were less reduced relative to the homologous WT rate.
We assessed whether the presence of the N-terminal bicysteine (C2) tag influenced the measurement of heterologous
fibril growth rates. We prepared fibril seeds from native WT
␣-syn and combined them with native WT and mutant ␣-syn
monomer proteins (without a C2 tag) in 96-h heterologous
fibril growth experiments matching the experimental design of
Fig. 10, D–F. We measured fibril growth by a BCA sedimentation assay (Fig. 11A) and ThioT fluorescence (Fig. 11B). The
relative differences in growth rates for untagged WT and
mutant ␣-syn monomer species were similar to those observed
with C2-␣-syn monomer species (Fig. 10, E and F). Sensitivity
limits do not allow comparison of fibril growth rates in 3-h
experiments, and we have not prepared fibrils from untagged
mutant ␣-syn to further characterize homologous and heterologous growth rates for the native mutant ␣-syn seeds. However,
the results with native WT ␣-syn seeds and mutant ␣-syn monomer indicate that measurements of relative growth rates with
C2-tagged ␣-syn monomer species reflect the growth rates for
native ␣-syn monomer species.
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Table 5
Rates of homologous and heterologous fibril growth in 3-h SeGMA assays
Rates of seed growth for homologous and heterologous seed plus monomer combinations were measured by FlAsH fluorescence for three different seed concentrations
(2.8 –11.5 g/ml) and a constant monomer concentration of 500 g/ml. Average rates were expressed as a percentage of the rate obtained for WT seeds extended by WT
monomer.
Rate of seed extension (%WT) at 3 h, mean (95% CI)

Homologous: matched seeds ⫹ monomer
Heterologous: WT seeds ⫹ mutant monomer
Heterologous: mutant seeds ⫹ WT monomer

WT

A30P

A53T

E46K

G51D

%

%

%

%

%

%

100 (91.7–108.3)

23 (18.6–27.4)
4.7 (0–9.6)
30 (26.4–33.6)

552.6 (481.6–623.6)
3.7 (0–8.7)
17.7 (6.2–29.2)

48 (42.5–53.5)
0.3 (0–1.1)
16 (13–19)

21 (17.8–24.2)
2.9 (1.7–4.1)
22 (19–25)

323 (302–344)
97 (91.4–102.6)
7.6 (2.4–12.8)

by mutant monomer proteins and that mutant seeds are also
extended inefficiently by WT monomer. These results provide important insight into a critical step regulating the
accumulation of ␣-syn fibrils. They demonstrate that fibril
growth is a highly ordered process. Although fibril growth
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probably depends on monomer-monomer interactions over
the ⬃60-amino acid sequence comprising the highly structured
␤-sheet region of ␣-syn fibrils (43, 44), it is very sensitive to
single-amino acid sequence changes in the N-terminal region.
The bicysteine tag has several advantages for monitoring the
kinetics of fibril formation. It is smaller than other fluorescent
tags, such as fluorescent proteins, and therefore has less potential to influence fibril structure and the kinetics of fibril formation. Commonly used amyloid-binding dyes, such as ThioT
or thioflavin S, depend on specific binding sites present on the
cross-␤-sheet conformation of the aggregated protein (45).
Thus, it is difficult to obtain accurate kinetic measurement for
smaller oligomeric species, which may lack ThioT-binding
sites. FlAsH is able to detect soluble oligomeric species that are
not detected by ThioT, indicating a greater sensitivity to monitor the formation of early and intermediate species in fibril
formation. The most important property of bipartite tetracysteine detection is the ability to sensitively detect growth of
either oligomer or fibril seeds by association of C2-␣-syn monomer. This property enables linear rates of seed extension to be
measured during very short incubation times (1–5 h) under
quiescent conditions, providing novel information about homologous and heterologous fibril growth rates for ␣-syn. BCA sedimentation assays support the reliability of FlAsH measurements for both WT and mutant fibril species, which is probably
explained by the fact that the bicysteine tag is located at least 30
amino acids away in the unstructured N-terminal end of ␣-syn
fibrils. Additional experiments comparing relative growth rates
of native WT ␣-syn seeds in the presences of WT and mutant
native ␣-syn monomer species also support the reliability of
SeGMA assays for investigating structural requirements of
fibril growth.
Previous studies have examined the effect of familial-PD
mutations on ␣-syn aggregation in paradigms involving the rate
of spontaneous conversion of monomeric protein to fibrils. Our
mutant seed extension data agree with previously published
studies with A30P, A53T, G51D, and H50Q, in which rates of
spontaneous fibrillization were measured in vitro. In our seed
growth assay, E46K demonstrated a slow rate of growth compared with WT, which is in contrast to other studies examining
rates of spontaneous fibril formation. It should be noted that
the rates measured in these previous studies represented a
combination of nucleation plus fibril growth rates, where
parameters such as the 50% conversion time (t1⁄2, hours or days)
or the lag time (hours or days) can be compared. However, we
also observed slower rates of spontaneous fibril formation by
E46K ␣-syn under shaking conditions, suggesting that differ-
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Figure 8. Rates of fibril growth for WT and mutant seeds in the presence
of 50% WT and 50% mutant C2-␣-syn monomer. The rate of fibril growth
was measured by FlAsH fluorescence after combining 11.5 g/ml seeds with
different combinations of WT and mutant monomer at a 1:1 ratio and a total
concentration of 500 g/ml. A, fibril growth rates for WT seeds combined with
50% WT and 50% of each different mutant monomer. Rates are compared
with the rate observed for WT seeds extended by 100% WT mutant monomer.
B, fibril growth rates for each mutant seed species when combined with 50%
WT monomer and 50% matched mutant monomer. Rates are compared with
the rate for WT seeds extended by 100% WT mutant monomer. The rates for
the monomer mixtures containing 50% each of WT and mutant monomer
were approximately the average of the two rates produced by 100% WT monomer and 100% mutant monomer, with no evidence of synergistic interactions
between different monomer species (mean ⫾ S.D. (error bars), n ⫽ 3, independent experiments ⫽ 1).

H50Q
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Table 6
Fibril accumulation in the homologous and heterologous seed plus monomer combinations after incubation for 96 h
Fibril accumulation in the homologous and heterologous seed plus monomer combinations were measured by FlAsH fluorescence after incubation of 11.5 g/ml seeds with
500 g/ml monomer without agitation for 96 h. Average rates were expressed as a percentage of the rate obtained for WT seeds extended by WT monomer (mean ⫾ 95%
CI, n ⫽ 9, independent experiments ⫽ 3).
Fibril accumulation (%WT) at 96 h, mean (95% CI)
WT

A30P

A53T

E46K

G51D

H50Q

%

%

%

%

%

%

Homologous: matched seeds ⫹ monomer
100 (87–113) 24.6 (15.9–33.4) 308.4 (276.9–339.8) 22.3 (18.3–26.4) 11.5 (10.6–12.4) 203.8 (186.8–220.8)
Heterologous: WT seeds ⫹ mutant monomer
18.6 (13.1–24.1) 40.0 (21.8–58.3)
1.3 (0.2–2.5)
10.8 (7.8–13.8) 100.2 (83.1–117.3)
Heterologous: mutant seeds ⫹ WT monomer
28.3 (20.3–36.2) 52.8 (40.9–64.8)
18.4 (8.9–27.9) 7.3 (6.5–8.0)
13.0 (9.4–16.7)

ences in fibril formation kinetics for this protein may be attributable to different conditions utilized for fibril formation studies. Different fibril formation conditions can lead to differences
in WT ␣-syn fibril structure as assessed by solid-state NMR (44,
46). Furthermore, variations in fibril structure could arise from
conditions driving ␣-syn fibril formation in vivo, not only for
mutant ␣-syn fibrils in familial PD, but also the occurrence of
␣-syn fibril accumulation in other synucleinopathies, such as
multiple system atrophy. The SeGMA assays reported herein
can be utilized to further investigate and compare structural

requirements for fibril growth of different ␣-syn fibril
conformers.
The high degree of sequence specificity observed in our heterologous seed extension experiments, where rates are measured over 3 h, has not been reported previously. The basis for
this specificity is probably related to the rigid ␤-sheet structure
observed in previous solid-state nuclear magnetic resonance
studies of ␣-syn fibrils (43, 44). Residues 30 –97 comprise the
core fibrillar region, with multiple rigid ␤-strands and loops.
Fibril growth thus requires newly associating monomer proJ. Biol. Chem. (2017) 292(22) 9034 –9050
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Figure 9. Time course of homologous and heterologous seeded fibril growth over 96 h. Homologous and heterologous mixtures of 11.5 g/ml C2-␣-syn
seeds and 500 g/ml C2-␣-syn monomer were incubated at 37 °C without agitation for varying lengths of time up to 96 h. Fibril growth at each time point was
determined by FlAsH fluorescence. The rate for each seed-monomer combination was compared with the rate of fibril growth for WT seeds incubated with WT
monomer. A–E, time course of fibril growth for homologous seed-monomer combinations demonstrated that the rates over longer incubation periods were
very similar to the rates observed in 3-h experiments (Fig. 5). Furthermore, faster and slower rates of fibril growth corresponded to higher and lower levels of
fibril accumulation as rates plateaued by 96 h. F–J, time course of fibril growth for WT seeds incubated with each of the different mutant monomer species. K–O,
time course of fibril growth for each of the different mutant seeds incubated with WT monomer. The time course of heterologous fibril growth over longer time
periods was also similar to the rates observed in 3-h experiments (Fig. 6). P–T, time course of fibril growth when each monomer species was incubated in the
absence of seeds (mean ⫾ S.E. (error bars), n ⫽ 3, independent experiments ⫽ 2).
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Figure 11. Relative rates of heterologous fibril growth for ␣-syn monomer species without a C2 tag are similar to the relative rates of C2-␣-syn
monomer species. 11.5 g/ml native WT ␣-syn seeds were combined with
500 g/ml native WT or mutant ␣-syn monomer and incubated at 37 °C
without agitation for 96 h. Fibril formation was assessed by a BCA sedimentation assay (A) and ThioT fluorescence (B). Relative rates of fibril
growth with untagged ␣-syn monomer species shown here are similar to
the rates observed for C2-␣-syn monomer species in the heterologous
assays shown in Fig. 10, D–F (mean ⫾ S.D. (error bars), n ⫽ 3, independent
experiments ⫽ 2).

teins to adopt a conformation that matches the ␤-strand structure of the fibril. Constraints on the ability of associating monomer to match the conformation of the fibril seed are likely to
result in slower association of ␣-syn monomers and faster monomer dissociation.
The effects of single-amino acid mismatches on fibril growth
were consistently maintained in 96-h experiments, indicat-
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ing that the structures of fibril seeds are maintained during
growth by the addition of heterologous monomer species.
Interpretation of these 96-h experiments is aided by the lack
of spontaneous nucleation under the conditions we used,
which could potentially interfere with measurement of
seeded fibril growth rates. The observation that rates are
consistently maintained over longer time periods supports
the conclusion that fibril structure is templated during heterologous monomer addition, with no evidence of conversion to the structures and rates produced under spontaneous
nucleation conditions.
Our findings are consistent with the observation that A53T
fibrils seed fibril formation by WT monomer more slowly than
WT fibrils seed WT monomer, as measured by sedimentation
assays over 1–10 days (21). Furthermore, Sidhu et al. (35)
observed inefficient heterologous cross-seeding for WT, A30P,
and A53T ␣-syn, relative to homologous rates. However, two
previous studies did not find reduced rates of heterologous
growth for at least some species. Ono et al. (34) observed that
heterologous mixtures of mutant fibrils and WT monomer
formed ThioT-binding fibrils at approximately the same rate as
homologous mixtures of fibrils and monomer, in a system that
utilized agitation in 20 mM Tris-HCl, pH 7.4, which is significantly different from our quiescent incubation in 20 mM Tris-
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Figure 10. Comparison of FlAsH measurements with two other measurements of C2-␣-syn fibril formation following seeded fibril growth for 96 h
further validates SeGMA assays. Homologous and heterologous mixtures of 11.5 g/ml seeds and 500 g/ml monomer were incubated at 37 °C without
agitation for 96 h. Fibril formation for each of the homologous and heterologous seed-monomer combinations was assessed by FlAsH fluorescence (A, D, and
G); BCA sedimentation assay, which measures fibril concentration based on the change in the supernatant concentration of C2-␣-syn after centrifugation at
100,000 ⫻ g (B, E, and H); and ThioT fluorescence (C, F, and I) (mean ⫾ S.D. (error bars), n ⫽ 3, independent experiments ⫽ 2).
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aggregated protein species cause neurodegeneration and the
role of soluble oligomers versus insoluble fibrils are still being
elucidated. A potential common pathogenic mechanism in
these diseases is the impairment of protein homeostasis networks caused by the burden of aggregated protein (52, 65),
which further impairs cellular function. Furthermore, recent
reviews have elaborated on the potential for prion-like transcellular propagation of fibrillar ␣-syn (66 – 68), a possible
mechanism underlying the progressive involvement of additional brain regions over time. These observations indicate that
approaches to decrease the burden of fibrillar protein accumulation could slow or stop disease progression.
Fibril growth is thus one of several important steps that can
be targeted to prevent the progressive accumulation and spread
of fibrillar protein species (69). The observed sensitivity to
sequence mismatches indicates that monomer association is
dependent on precise alignment of the associating polypeptide
chains over the region of amino acid sequence (Ala30–Ala53)
included in this study. In the setting of these strict structural
requirements, fibril growth could be substantially inhibited by a
small molecule that interacts with either free monomeric protein or the seed surface to which a new monomer must bind in
order to extend the seed. Effective inhibitors could alter the
molecular interaction between associating polypeptide chains
or modify their conformation in a way that disrupts the alignment necessary for fibril growth. The bipartite tetracysteine
approach enables additional studies to further define structurefunction relationships for ␣-syn association during seed extension and could serve as a platform for the development of fibril
growth inhibitors as therapeutics in PD.

Experimental procedures
PCR primers for generating N-terminal C2-␣-syn
To add the 6-amino acid bicysteine tag to the N terminus of
WT-␣-syn (5⬘-MGCCGG-␣-syn-3⬘), we used PCR amplification using the pRK172-WT-␣-syn plasmid plus the following
primers: 5⬘-AAAAACATATGGGCTGCTGCGGCGGCATGGATGTATTCATGAAAGGA-3⬘ (forward primer) and 5⬘AAAAAAAGCTTTTAGGCTTCAGGTTCGTAGTC-3⬘ (reverse primer). The PCR product was subcloned into the
pRK172 vector plasmid, and the DNA was sequenced to verify
that the insert had been successfully ligated into pRK172.
Mutagenesis for untagged ␣-syn mutants and C2-␣-syn
mutants (A53T, A30P, E46K, G51D, and H50Q)
To generate untagged ␣-syn mutants or C2-tagged ␣-syn
mutants, site-directed mutagenesis using the QuikChange sitedirected mutagenesis protocol (Stratagene, La Jolla, CA) was
performed on the pRK172-WT-␣-syn plasmid or the pRK172C2-WT-␣-syn plasmid (see above) with the following primers:
G1573 A (A53T mutation), 5⬘-GTGGTGCATGGTGTGACAACAGTGGCTGAGA-3⬘ (forward primer) and 5⬘-TCTCAGCCACTGTTGTCACACCATGCACCAC-3⬘ (reverse primer);
G883 C (A30P mutation), 5⬘-GGGTGTGGCAGAAGCACCAGGAAAGACAAAAGA-3⬘ (forward primer) and 5⬘-TCTTTTGTCTTTCCTGGTGCTTCTGCCACACCC-3⬘ (reverse
primer); G1363 A (E46K mutation), 5⬘-GGCTCCAAAACCAAGAAGGGAGTGGTGCATG-3⬘ (forward primer) and 5⬘J. Biol. Chem. (2017) 292(22) 9034 –9050
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HCl, pH 8.0, with 100 mM NaCl. Flagmeier et al. (36) observed
heterologous fibril growth rates that were equal to or lower
than homologous growth rates, in a system that used higher
seed/monomer ratios with quiescent incubation in 20 mM
phosphate buffer at pH 6.5. The use of agitation and higher
concentrations of monomer may produce more complex
effects of seeds on the rates of both nucleation and growth.
Furthermore, differences in incubation conditions used for
nucleation of fibril formation, such as buffer and NaCl concentration, may produce differences in fibril structures (44, 47–50),
which in turn may have different effects on the relative rates of
heterologous monomer association.
The accumulation of ␣-syn fibrils is the defining histopathologic feature of not only idiopathic PD, but also familial PD
caused by the A53T, A30P, E46K, H50Q, and G51D mutations.
The observed decrease in seed extension rates for the A30P,
E46K, and G51D mutations indicates that these single-amino
acid changes cause fibril accumulation in vivo through mechanisms independent of effects on fibril growth rates. This is further supported by the decreased rates of heterologous seed
extension for all mutants, indicating that interactions
between mutant and WT ␣-syn proteins do not significantly
contribute to fibril accumulation in dominantly inherited
PD. For example, the faster rate of oligomer formation
observed for A30P ␣-syn occurs in the setting of slow fibril
growth rates by association of either A30P or WT ␣-syn
monomer. This predicts greater accumulation of oligomers
than fibrils in individuals with the A30P mutation. However,
the A30P mutation does cause accumulation of ␣-syn fibrils,
which has been demonstrated by electron microscopy analysis and by detection of insoluble ␣-syn in postmortem
human brain tissue (51).
Dominantly inherited SNCA mutations could cause fibril
accumulation by multiple mechanisms other than effects on
fibril growth rate. For example, rates of both nucleation and
seedextensiondependontheinvivoconcentrationoffreemonomer, which is likely to be influenced by protein turnover rates
(52), monomer-lipid interactions (53, 54), formation of tetrameric ␣-syn complexes (55, 56), and chaperone interactions
(57, 58). Similarly, interactions with chaperone proteins and
protein clearance pathways may influence the clearance
rates of soluble oligomeric species and fibrils (59 – 62).
Finally, alterations in post-translational modifications, particularly
phosphorylation (63, 64), may affect fibril accumulation in vivo.
Translation of the FlAsH system into a cell culture model
expressing C2-␣-syn could enable further investigation of
the effects of mutations on ␣-syn fibrillization within a cellular environment, enabling the role of additional in vivo
factors to be assessed.
Accumulation of misfolded protein may have a pathogenic
role in a wide range of both hereditary and sporadic neurodegenerative disorders, including PD, Alzheimer’s disease, frontotemporal lobar dementias, and hereditary polyglutamine
repeat disorders, such as Huntington’s disease. The identification of dominantly inherited mutations in these disorders provides further support for the role of protein aggregation pathways in disease pathogenesis, although mechanisms by which
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CATGCACCACTCCCTTCTTGGTTTTGGAGCC-3⬘ (reverse
primer); G1523 A (G51D mutation), 5⬘-GGGAGTGGTGCATGATGTGGCAACAGTGG-3⬘ (forward primer) and 5⬘-CCACTGTTGCCACATCATGCACCACTCCC-3⬘ (reverse primer);
T1503 G (H50Q mutation), 5⬘-GGAGGGAGTGGTGCAGGGTGTGGCAACAG-3⬘ (forward primer) and 5⬘-CTGTTGCCACACCCTGCACCACTCCCTCC-3⬘ (reverse primer). All
mutations were confirmed by sequencing of the entire ␣-syn
coding region.
Preparation of WT ␣-syn, untagged mutant ␣-syn, C2-WT, and
C2-mutant-␣-syn protein

Preparation of ␣-syn oligomers and ␣-syn fibrils

␣-Syn fibrils were prepared by incubating 2000 g/ml purified monomer in 20 mM Tris-HCl, pH 8.0, 100 mM NaCl (fibril
formation buffer) at 37 °C in an Eppendorf Thermomixer with
constant shaking at 1000 rpm for 72–96 h. For the C2-␣-syn
fibril preparation, 1 mM DTT was added to the fibril formation
buffer. For preparation of oligomers, the 2000 g/ml purified
monomer was incubated in 20 mM Tris-HCl, pH 8.0, 100 mM
NaCl, 1 mM DTT for 32–36 h. For analysis of the time course of
fibril formation, 75 l of samples were removed at each time
point and stored at ⫺80 °C before analysis in the fluorescence
assay. To determine the concentration of fibrils, samples were
centrifuged at 15,000 ⫻ g for 15 min at 4 °C to separate fibrils
from monomer. The concentration of ␣-syn monomer in the
supernatant was determined in a Micro BCA protein assay
(Thermo Scientific Pierce Micro BCA kit, catalog no. 23235)
according to the manufacturer’s instructions, using the manufacturer-supplied bovine serum albumin (BSA) for the standard
curve. The measured decrease in ␣-syn monomer concentration was used to determine the concentration of fibrils in each
sample.
Determination of Kapp of FlAsH to preformed C2-␣-syn fibrils
Saturation binding assays were performed to quantify the
binding affinity of 4,5-bis(1,3,2-dithiarsolan2-yl)fluorescein
(FlAsH-EDT2) dye to preformed C2-␣-syn fibrils. Fibrils produced by incubation of C2-␣-syn protein for 72 h were centrifuged at 15,000 ⫻ g for 15 min at 4 °C. The fibril pellet was
resuspended in 100 l of fibril formation buffer (20 mM TrisHCl, pH 8.0, 100 mM NaCl) and sonicated in a Qsonica (model
Q700) sonicator with a cup horn (5.5-inch) attachment for
1 min at power setting 50. Then increasing concentrations
(0 –180 g/ml) of sonicated fibril seeds were combined with a
FlAsH assay mixture consisting of 3.5 mM tris(2-carboxyethyl)
phosphine, 1 mM EDT, 1 mM EDTA, 25 nM FlAsH-EDT2, and
200 mM Tris-HCl, pH 8.0, in a final volume of 100 l. After
incubation at room temperature for 1 h in Corning Black
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FlAsH fluorescence assay
The profluorescent biarsenical dye FlAsH-EDT2 (Invitrogen
TC-FlAsHTM II in-cell tetracysteine tag detection kit, catalog
no. T34561) was used in bipartite tetracysteine detection assays
to quantify oligomer and fibril formation. Samples (5–25 l)
were combined with a FlAsH assay mixture consisting of 3.5
mM tris(2-carboxyethyl)phosphine, 1 mM EDT, 1 mM EDTA, 25
nM FlAsH-EDT2, and 200 mM Tris-HCl, pH 8.0, in a final volume of 100 l. After incubation at room temperature for 1 h in
Corning Black 96-well plates (Fisher 07-200-762), FlAsH fluorescence was detected in a BioTek plate reader using a 485/
20-nm excitation filter, a 528/20-nm emission filter, top 510nm optical setting, and gain setting 100.
ThioT fluorescence assay
Samples were incubated in Corning Black 96-well plates
(Fisher, catalog no. 07-200-762) with 18 M ThioT in 30 mM
Tris-HCl, pH 7.4. A total volume of 100 l/well was incubated
at room temperature for 1 h, and ThioT fluorescence was measured in a BioTek plate reader using a 440/30-nm excitation
filter, a 485/20-nm emission filter, and top 50% optical setting.
In the case of the spontaneous fibril formation experiment (Fig.
1), the gain setting was set to 60, whereas, in subsequent experiments, the gain was set to 80. Different gain settings produced
different afu values but did not change the signal/background
ratio (data not shown).
Isolation and characterization of oligomers using SEC
Samples containing ␣-syn oligomers were fractionated using
a GE Healthcare ÄKTA purifier FPLC system, GE Unicorn version 5.20 software, and a GE Superdex 200 10/300 GL (product
17-5175-01) size exclusion column. The column was equilibrated in at least 50 ml of column buffer (20 mM Tris-HCl, pH
8.0, 100 mM NaCl, 0.1% Triton X-100) before analysis. Samples
(400 l) to be analyzed by SEC were prepared by centrifugation
at 100,000 ⫻ g for 30 min at 4 °C in a Beckman TLA-55 rotor.
The supernatant was collected, Triton X-100 was added to a
final concentration of 0.1%, and protease inhibitor mixture
(Sigma, catalog no. P2714) was added to a final concentration of
1⫻. The samples were then injected onto the SEC column using
a 200-l injection loop and fractionated at a flow rate of 0.5
ml/min. Twenty-five fractions (0.5 ml each) were collected
beginning at 4.7 ml (0.2 column volumes) after the injection of
sample. The GE Superdex 200 10/300 GL column was calibrated by injection of ovalbumin (44,000), aldolase (158,000),
and ferritin (440,000) molecular weight standards.
WB analysis of Superdex fractions
SEC fractions were analyzed by WB using 26-well Criterion
4 –20% Tris-HCl, SDS-polyacrylamide gels (Bio-Rad) (72).
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Recombinant ␣-syn protein was prepared using methods
described previously (70, 71) by transforming BL21(DE3)RIL
bacterial cells with the pRK172 plasmid containing the desired
␣-syn construct (WT, untagged mutant, C2-WT, C2-mutant).
The recombinant proteins were purified by heat denaturation
and precipitation of bacterial proteins, followed by ion-exchange chromatography. Purified monomeric ␣-syn was dialyzed and stored at ⫺80 °C before use.

96-well plates (Fisher, catalog no. 07-200-762), FlAsH fluorescence was detected as described below. As a control, FlAsH
fluorescence at 0 g/ml fibril concentration was used to obtain
the specific binding fluorescence measurement. The data were
fit to the equation, y ⫽ Bmax ⫻ x/(x ⫹ Kd) using non-linear
regression analysis with GraphPad Prism version 4.0 to obtain
an apparent affinity constant measurement.

Structural determinants of ␣-synuclein fibril growth
Electrophoresed proteins were transferred to nitrocellulose
membranes and incubated with mouse anti-␣-syn antibody
syn303 (a gift of Dr. Virginia M.-Y. Lee), followed by horseradish peroxidase-conjugated anti-mouse secondary antibody
(Jackson Immunoresearch). Bound secondary antibody was
detected by enhanced chemiluminescence (ECL) using Immobilon Western ECL Substrate (Millipore). Blots were imaged
with an Eastman Kodak Co. Image Station 4400, and the intensity of individual bands was compared using Kodak 1D analysis
software.
AFM analysis of ␣-syn fibrils and oligomers

Preparation of sonicated fibril seeds for SeGMA assays
Fibrils produced by incubation of ␣-syn protein for 72 h were
centrifuged at 15,000 ⫻ g for 15 min at 4 °C. The fibril pellet was
resuspended in 100 l of fibril formation buffer (20 mM TrisHCl, pH 8.0, 100 mM NaCl) and sonicated in a Qsonica (model
Q700) sonicator with a cup horn (5.5-inch) attachment for 5
min at power setting 50. The sonicated fibril seeds were further
diluted to a working concentration of 285 g/ml in 20 mM TrisHCl, pH 8.0, 100 mM NaCl, 0.1% Triton X-100 and stored at
4 °C before use.
SeGMA assays
Seed extension rates were measured by combining 5 l of
seed samples (sonicated fibrils or SEC fractions) with 20 l of
purified C2-␣-syn monomer in thin-wall PCR tubes and incubating at 37 °C for the indicated times in a Bio-Rad thermal
cycler. Control reactions contained the appropriate buffer solution in place of seed samples. Additional control reactions were
prepared by combining seed samples and purified C2-␣-syn
monomer without incubation at 37 °C. SeGMA reaction
samples were mixed by pipetting before removing 20 l for
addition to the FlAsH assay mixture in 96-well plates. For
homologous SeGMA assays, the seeds and C2-␣-syn monomer were matched (e.g. A53T seeds with A53T C2-␣-syn
monomer), whereas for heterologous SeGMA assays, the
seeds and C2-␣-syn monomer are different (e.g. A53T seeds
with WT C2-␣-syn monomer or WT seeds with A53T C2-␣syn monomer).
Estimating the size of WT and mutant fibril seeds using DLS
A Zetasizer Nano ZS instrument (Malvern Instruments) was
used to measure the hydrodynamic diameter of sonicated WT
and mutant C2-␣-syn seeds at 25 °C. Seeds were prepared by

Zⴕ-factor determination
We used Z⬘-factor as a screening window coefficient to measure statistical separation between the 3- and 0-h incubated
SeGMA samples using FlAsH and ThioT fluorescence measurements. The formula for calculation of the dimensionless Z⬘-factor (22) is as follows.
Z⬘ ⫽ 1 ⫺

3 ⫻ 共 S.D. sample ⫹ S.D.control)
兩Meansample ⫺ Meancontrol兩

(Eq. 1)

Comparison of FlAsH fluorescence intensity in the presence of
WT and mutant C2-␣-syn fibrils
Mutant and WT C2-␣-syn fibrils were centrifuged at
15,000 ⫻ g for 15 min at 4 °C, and the fibril pellets were resuspended in 50 l of fibril formation buffer (20 mM Tris-HCl, pH
8.0, 100 mM NaCl). The samples were sonicated in a Qsonica
(model Q700) sonicator with a cup horn (5.5-inch) attachment
for 1 min at power setting 50. The sonicated fibril seeds were
then diluted to a concentration of ⬃14.5 g/ml and incubated
with 25 nM FlAsH dye for 1 h at room temperature, before
measurement of FlAsH fluorescence. FlAsH fluorescence measured for each mutant C2 fibril sample was then compared with
the fluorescence obtained from WT C2 fibrils.
Time course of seeded fibril growth reactions
To assess seeded fibril growth over longer time periods, 20 l
of seeds (11.5 g/ml) were combined with 80 l of monomer
(500 g/ml) for each seed-monomer combination in 96-well
polypropylene plates (Fisher, catalog no. 12-565-368) and incubated at 37 °C under quiescent conditions. Time points were
collected at 0, 3, 6, 9, 18, 42, 54, 72, and 96 h for the time course,
and the plates were stored at 4 °C before use in further assays.
Similarly, 100-l reactions were set up in microcentrifuge tubes
(Beckman, catalog no. 357448) to assess fibril accumulation at
96 h using FlAsH, BCA sedimentation, and ThioT assays. Each
sample was mixed by pipetting before removing 5 l of sample
for the FlAsH assay and using 20 l for the ThioT assay. The
remainder was used for the BCA sedimentation assay. Each
seed-monomer combination was set up in triplicate for each
time point.
BCA sedimentation assay
To assess fibril accumulation in each seed-monomer condition after 96 h, microcentrifuge tubes (0 and 96 h) were spun at
100,000 ⫻ g for 20 min at 4 °C in a Beckman TLA-55 rotor.
Then 15 l of supernatant was added to the BCA assay (Micro
BCA kit, catalog no. 23235) to determine ␣-syn monomer concentration using a standard curve produced with manufacturer-supplied BSA. The measured decrease in ␣-syn monomer
concentration was used to determine the concentration of
fibrils accumulated in the 96-h fibril reaction mixtures.
J. Biol. Chem. (2017) 292(22) 9034 –9050
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AFM images were collected using an Asylum Research
atomic force microscope with the aid of Asylum Research MFP
3D software. Mica coverslips (Ted Pella Inc., catalog no. 50)
were mounted onto Fisher brand Plain Superclean microscope
slides with superglue. Samples of SEC-purified oligomers or
fibrils were diluted in 20 mM Tris-HCl, 100 mM NaCl, 0.1%
Triton X. Then 50 l of sample was applied to the freshly
exposed mica surface, incubated for 30 min at room temperature in a humidified chamber, and then washed three times
with 50 l of water. The coverslips were then dried overnight
in a desiccating chamber. Images were obtained by scanning
at 1 Hz.

sonicating WT and mutant C2-␣-syn fibrils and were diluted in
20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.1% Triton-X for measurements. Each measurement was performed on at least two
independent preparations of each seed species, and all samples
were scanned 3–5 times in the DLS instrument.
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